15n: Hsp110/HDAC6 Dual-Target Inhibitor Data for Pulmonary Arterial Hypertension

A dataset from a 2026 study by Mengqi Li, describing the design and testing of a novel dual-target inhibitor compound for pulmonary arterial hypertension. The data likely contains results from structure-activity relationship studies, in vitro assays, and in vivo experiments evaluating the compound's effect on vascular remodeling. The dataset is published under a CC-BY-NC-4.0 license on figshare.

Use Cases

• Training models to predict compound efficacy based on structural-activity relationship data.
• Analyzing synergistic effects of dual-target inhibition on STAT3 signaling pathway suppression.
• Benchmarking new inhibitor compounds against the identified lead compound '15n'.
• Studying the relationship between Hsp110-STAT3 interaction and HDAC6 activity in vascular remodeling.

Strengths

• Data is associated with a specific, potent lead compound identified as '15n'.
• The study includes both in vitro and in vivo experimental results.
• Dataset is published under a clear CC-BY-NC-4.0 license.

Limitations

• Dataset is very small at 2.2 KB, suggesting limited scope.
• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.

Provenance

Source

figshare

Collection Method

Likely contains experimental data from structure-activity relationship studies and biological assays.

Freshness

Last updated 2026-05-11 11:03:34; freshness should be verified.